Breast Cancer Adjuvant Hormonotherapy : Tamoxifen and the Anti-aromatases Pharmacokinetics, Correlation With the Pharmacogenetic Characteristics PHACS Protocol : Pharmacology of Adjuvant Hormonotherapy in Breast Cancer.

Trial Profile

Breast Cancer Adjuvant Hormonotherapy : Tamoxifen and the Anti-aromatases Pharmacokinetics, Correlation With the Pharmacogenetic Characteristics PHACS Protocol : Pharmacology of Adjuvant Hormonotherapy in Breast Cancer.

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Anastrozole (Primary) ; Exemestane (Primary) ; Letrozole (Primary) ; Tamoxifen (Primary)
  • Indications Breast cancer
  • Focus Pharmacogenomic; Pharmacokinetics
  • Acronyms PHACS
  • Most Recent Events

    • 01 Mar 2018 Status changed from active, no longer recruiting to completed.
    • 09 Dec 2017 Results (n=1977) assessing relationships between pharmacogenetics (PG), pharmacokinetics (PK) and toxicity in breast cancer patients, were presented at the 40th Annual San Antonio Breast Cancer Symposium.
    • 09 Jun 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top